# FDA ODAC vote on AstraZeneca’s Lynparza combo in prostate cancer

- Link: https://www.directorstalkinterviews.com/fda-odac-vote-on-astrazenecas-lynparza-combo-in-prostate-cancer/4121117642
- Published: 2023-05-02T08:30:22+01:00
- Author: Amilia Stone

**[AstraZeneca plc](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l)(**
[LON:AZN](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l))
has announced that the Food and Drug Administration’s (FDA) Oncologic Drugs Advisory
Committee (ODAC) has recognised a favourable benefit risk profile for AstraZeneca
and MSD’s _Lynparza_ (olaparib) plus abiraterone and prednisone or prednisolone 
for the treatment of adult patients with BRCA-mutated (BRCAm) metastatic castration-
resistant prostate cancer (mCRPC) based on the PROpel Phase III trial. The Committee
voted 11 to 1, with 1 abstaining, that the indication should be limited to patients
whose tumours have a BRCA mutation.

In August 2022, the FDA accepted the supplemental New Drug Application (sNDA) for
_Lynparza_ based on positive results from the pivotal PROpel trial, also published
in NEJM Evidence. The ODAC provides the FDA with independent, expert advice and 
recommendations on marketed and investigational medicines for use in the treatment
of cancer. The FDA is not bound by the Committee’s guidance but takes its advice
into consideration. AstraZeneca and MSD will continue to work with the FDA as it
completes its review of the application.

> Neal Shore, Chief Medical Officer of Urology and Surgical Oncology for Genesis
> Care, US and PROpel trial investigato**r**, said: “Today’s recommendation by the
> ODAC is disappointing news for clinicians and prostate cancer patients alike. 
> Preventing or delaying radiographic progression is an important clinical endpoint
> in assessing oncologic treatment and is very relevant to patients, their caregivers
> and their families. It is essential that physicians and patients have an opportunity
> to choose treatment with the goal of optimising cancer care outcomes.”

> **Susan Galbraith, Executive Vice President, Oncology R&D, AstraZeneca said**:“
> Novel treatment options are urgently needed for patients with metastatic castration-
> resistant prostate cancer. While we are pleased with the recognition of the benefit
> of _Lynparza_ plus abiraterone for patients with BRCA-mutated metastatic castration-
> resistant prostate cancer, we are disappointed with the outcome of today’s ODAC
> meeting. We strongly believe in the results of the PROpel trial, which demonstrated
> the clinically meaningful benefit for this combination in a broad population of
> patients regardless of biomarker status.”

> **Eliav Barr, Senior Vice President, Head of Global Clinical Development and Chief
> Medical Officer, MSD Research Laboratories, said** “With the incidence and mortality
> of prostate cancer set to double in the coming decades, it is critical that we
> bring new treatment options with the potential to reduce the risk of disease progression
> or death to patients at the earliest possible moment in their care. While we are
> pleased that the ODAC recommended _Lynparza_ for patients with metastatic castration-
> resistant prostate cancer who have BRCA mutations, we believe in the potential
> of _Lynparza_ plus abiraterone for a broad range of patients with metastatic castration-
> resistant prostate cancer, based on the results of PROpel. We look forward to 
> the outcome of the FDA’s review of the application.”

Results from the PROpel trial showed a statistically significant and clinically 
meaningful 34% reduction in the risk of radiographic disease progression or death
with _Lynparza_ plus abiraterone with prednisone or prednisolone, versus abiraterone
alone in patients with mCRPC (hazard ratio [HR] 0.66; 95% confidence interval [CI]
0.54-0.81; p<0.001). Median radiographic progression-free survival (rPFS) was 24.8
months and 16.6 months, respectively.^(1)

Further results from the final prespecified overall survival (OS) analysis presented
at ASCO Genitourinary Cancers Symposium 2023 showed _Lynparza_ plus abiraterone 
and prednisone or prednisolone demonstrated median OS of 42.1 months versus 34.7
months for abiraterone plus placebo. This result represents a 7.4-month absolute
difference in median OS versus a standard of care (47.9% maturity, HR of 0.81, 95%
CI 0.67-1.00; p=0.0544). While this numerical increase in median OS did not achieve
statistical significance, it builds on the meaningful survival gains achieved for
patients in this setting treated with abiraterone alone, a current standard of care.

In exploratory analyses of the BRCAm subgroup, _Lynparza_ plus abiraterone demonstrated
improvements in both rPFS (HR of 0.23, 95% CI, 0.12-0.43) and OS (HR of 0.29, 95%
CI, 0.14-0.56). In the non-BRCAm subgroup, _Lynparza_ plus abiraterone also showed
improvements in rPFS (HR of 0.76, 95% CI, 0.61-0.94), and a modest trend for OS (
HR of 0.91, 95% CI, 0.73-1.13).

The safety and tolerability of _Lynparza_ plus abiraterone in PROpel was in line
with that observed in prior clinical trials and the known profiles of the individual
medicines.

_Lynparza_ in combination with abiraterone and prednisone or prednisolone is approved
in the EU and several other countries for the treatment of adult patients with mCRPC
based on the PROpel trial.

Share on: